|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Sigma-Aldrich Corporation (NasdaqGS:SIAL), a producer of biochemical and organic chemical products used in scientific and genomic research, biotechnology, pharmaceutical development, and diagnostics. |
|---|---|
| Transferring Party | Molecular Medicine BioServices, Inc., a biopharmaceutical contract manufacturing organization. |
| Sector | Diagnostics |
| Date | May 9, 2007 |
| Analysis Enhances Sigma-Aldridge's biologics capabilities, with new expertise in the development of viral products, with DNA, RNA and critical active ingredients for the production of novel vaccines and gene therapies. Terms not disclosed. MMB's sales are $12m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |